1
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
Condition(s):Amyotrophic Lateral SclerosisLast Updated:March 15, 2024Recruiting
Include Studies Not Open or Pending
Condition(s):Amyotrophic Lateral SclerosisLast Updated:March 15, 2024Recruiting
Condition(s):Alcohol Use Disorder (AUD); AlcoholismLast Updated:August 15, 2023Recruiting
Condition(s):Methamphetamine-dependenceLast Updated:January 8, 2024Recruiting
Condition(s):Myelopathy; Spinal Cord DiseasesLast Updated:January 13, 2022Recruiting
Condition(s):Long COVID; Post COVID Condition; Post Acute Sequelae of COVID-19Last Updated:October 2, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.